FatiguePhase 3NCT01781468
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase 3 study testing armodafinil 150 mg and armodafinil 250 mg in people with Fatigue, run by Alliance for Clinical Trials in Oncology at 365 sites in United States.
Trial summary
This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fatigue
- What is being tested?
- armodafinil 150 mg and armodafinil 250 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 328 participants
- Where
- 365 sitesUnited States
- Study dates
- 21 Jun 2013to 15 Dec 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma who are clinically stable and have completed radiation therapy (excluding stereotactic radiosurgery) > 21 days and =< 24 months prior to enrollment; NOTE: clinical stability will be defined as a stable or improved Karnofsky performance status (KPS) compared to the prior month
- >= 6 score on the worst fatigue question of the BFI (Brief Fatigue Inventory, question 3); it is not required for the patient to complete the entire BFI to meet this criterion
- Undergone surgery (gross total or subtotal resection) or biopsy and will have been treated with concurrent radiation therapy and chemotherapy as standard of care for glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma patients; Note: radiation must be completed, but chemotherapy is allowed; patients who are currently using Optune device will be eligible to participate in this trial
- Negative serum pregnancy test done =< 7 days prior to registration only for women determined to be of childbearing potential by their treating physician
- Ability to complete questionnaire(s) by themselves or with assistance
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 or 3
Show all 9Show fewer
- Provide informed written consent
- Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
- Stable dose of corticosteroid >= 14 days prior to registration
Who cannot join
None listed.
Trial locations and contacts
365 sites in 1 country.
300 sites in 1 country
United States300 sites
Hawaii Oncology Inc-Pali Momi
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
Avera Cancer Institute-Aberdeen
Aberdeen, South Dakota, 57401
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Cleveland Clinic Akron General
Akron, Ohio, 44307
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic PC - Ames
Ames, Iowa, 50010
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Mission Hospital Inc-Memorial Campus
Asheville, North Carolina, 28801
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital
Atlanta, Georgia, 30342
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Augusta University Medical Center
Augusta, Georgia, 30912
Dell Seton Medical Center at The University of Texas
Austin, Texas, 78701
Austin Cancer Centers-Central Austin
Austin, Texas, 78702
Austin Cancer Centers-North
Austin, Texas, 78758
The NeuroMedical Center-Clinic
Baton Rouge, Louisiana, 70810
Bronson Battle Creek
Battle Creek, Michigan, 49017
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Saint Charles Health System
Bend, Oregon, 97701
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Billings Clinic Cancer Center
Billings, Montana, 59101
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Boca Raton Regional Hospital
Boca Raton, Florida, 33486
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Tufts Medical Center
Boston, Massachusetts, 02111
Boston Medical Center
Boston, Massachusetts, 02118
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Highline Medical Center-Main Campus
Burien, Washington, 98166
Mills-Peninsula Medical Center
Burlingame, California, 94010
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Illinois CancerCare-Canton
Canton, Illinois, 61520
Caro Cancer Center
Caro, Michigan, 48723
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Northwestern University
Chicago, Illinois, 60611
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Community Cancer Institute
Clovis, California, 93611
University Oncology Associates
Clovis, California, 93611
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
University of Missouri - Ellis Fischel
Columbia, Missouri, 65212
Riverside Methodist Hospital
Columbus, Ohio, 43214
John Muir Medical Center-Concord Campus
Concord, California, 94520
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, 03301
Mercy Hospital
Coon Rapids, Minnesota, 55433
Baptist Health Corbin
Corbin, Kentucky, 40701
Greater Regional Medical Center
Creston, Iowa, 50801
Michiana Hematology Oncology PC-Crown Point
Crown Point, Indiana, 46307
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Carle on Vermilion
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Florida Hospital Memorial Medical Center
Daytona Beach, Florida, 32117
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Ascension Saint John Hospital
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Elkhart Clinic
Elkhart, Indiana, 46514-2098
Michiana Hematology Oncology PC-Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Aurora Health Center-Fond du Lac
Fond du Lac, Wisconsin, 54937
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Unity Hospital
Fridley, Minnesota, 55432
Gibbs Cancer Center-Gaffney
Gaffney, South Carolina, 29341
Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia, 30501
Kaiser Permanente-Gaithersburg Medical Center
Gaithersburg, Maryland, 20879
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534
Altru Cancer Center
Grand Forks, North Dakota, 58201
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Cancer Research Consortium of West Michigan NCORP
Grand Rapids, Michigan, 49503
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29601
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Cherry Tree Cancer Center
Hanover, Pennsylvania, 17331
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
21st Century Oncology-Henderson
Henderson, Nevada, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
AdventHealth Hendersonville
Hendersonville, North Carolina, 28792
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
Hawaii Cancer Care Inc-POB II
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii, 96817
Hawaii Oncology Inc-Kuakini
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
New Hampshire Oncology Hematology PA-Hooksett
Hooksett, New Hampshire, 03106
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546
Freeman Health System
Joplin, Missouri, 64804
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Novant Health Oncology Specialists-Kernersville
Kernersville, North Carolina, 27284
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Regional Cancer Center at Indian Path Community Hospital
Kingsport, Tennessee, 37660
Vidant Oncology-Kinston
Kinston, North Carolina, 28501
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
Thompson Cancer Survival Center - West
Knoxville, Tennessee, 37932
Community Howard Regional Health
Kokomo, Indiana, 46904
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
UC San Diego Moores Cancer Center
La Jolla, California, 92093
IU Health La Porte Hospital
La Porte, Indiana, 46350
Providence Regional Cancer System-Lacey
Lacey, Washington, 98503
LRGHealthcare-Lakes Region General Hospital
Laconia, New Hampshire, 03246
Lakeland Regional Health Hollis Cancer Center
Lakeland, Florida, 33805
Kaiser Permanente - Largo Medical Center
Largo, Maryland, 20774
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89106
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
21st Century Oncology
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, 89121
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, 89128
Ann M Wierman MD LTD
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148-2405
21st Century Oncology-Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Thompson Oncology Group-Lenoir City
Lenoir City, Tennessee, 37772
Central Maine Medical Center
Lewiston, Maine, 04240
Baptist Health Lexington
Lexington, Kentucky, 40503
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Nebraska Cancer Research Center
Lincoln, Nebraska, 68510
Loma Linda University Medical Center
Loma Linda, California, 92354
PeaceHealth Saint John Medical Center
Longview, Washington, 98632
Baptist Health Louisville
Louisville, Kentucky, 40207
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Baptist Health Madisonville/Merle Mahr Cancer Center
Madisonville, Kentucky, 42431
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Saint Mary's Oncology/Hematology Associates of Marlette
Marlette, Michigan, 48453
UP Health System Hematology Oncology Marquette
Marquette, Michigan, 49855
UP Health System Marquette
Marquette, Michigan, 49855
Culicchia Neurological Clinic LLC
Marrero, Louisiana, 70072
West Jefferson Medical Center
Marrero, Louisiana, 70072
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, 43537
Kaiser Permanente Tysons Corner Medical Center
McLean, Virginia, 22102
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Memorial Regional Cancer Center Day Road
Mishawaka, Indiana, 46545
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Memorial Medical Center
Modesto, California, 95355
Trinity Medical Center
Moline, Illinois, 61265
Monticello Cancer Center
Monticello, Minnesota, 55362
West Virginia University Healthcare
Morgantown, West Virginia, 26506
Novant Health Oncology Specialists-Mount Airy
Mount Airy, North Carolina, 27030
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149
Louisiana State University Health Science Center
New Orleans, Louisiana, 70112
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Regional Hematology and Oncology PA
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Southwest VA Regional Cancer Center
Norton, Virginia, 24273
Thompson Oncology Group-Oak Ridge
Oak Ridge, Tennessee, 37830
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Alegent Health Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131
Saint Joseph Hospital - Orange
Orange, California, 92868
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Saint Charles Hospital
Oregon, Ohio, 43616
Providence Willamette Falls Medical Center
Oregon City, Oregon, 97045
Florida Hospital Orlando
Orlando, Florida, 32803
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin, 54904
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Baptist Health Paducah
Paducah, Kentucky, 42003
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Sacred Heart Hospital
Pensacola, Florida, 32504
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Mercy Health Perrysburg Cancer Center
Perrysburg, Ohio, 43551
Illinois CancerCare-Peru
Peru, Illinois, 61354
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Arizona Oncology-Deer Valley Center
Phoenix, Arizona, 85027
Michiana Hematology Oncology PC-Plymouth
Plymouth, Indiana, 46563
Jefferson Healthcare
Port Townsend, Washington, 98368
Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon, 97210
Providence Portland Medical Center
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Kaiser Permanente Northwest
Portland, Oregon, 97227
Kootenai Cancer Center
Post Falls, Idaho, 83854
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
MultiCare Good Samaritan Hospital
Puyallup, Washington, 98372
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, 54868
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic
Rochester, Minnesota, 55905
Highland Hospital
Rochester, New York, 14620
University Radiation Oncology
Rochester, New York, 14626
University of Rochester
Rochester, New York, 14642
Unspecified Site
Rockville, Maryland, 20852
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Ascension Saint Mary's Hospital
Saginaw, Michigan, 48601
Oncology Hematology Associates of Saginaw Valley PC
Saginaw, Michigan, 48604
Lakeland Medical Center Saint Joseph
Saint Joseph, Michigan, 49085
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Heartland Regional Medical Center
Saint Joseph, Missouri, 64507
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
Kootenai Cancer Clinic
Sandpoint, Idaho, 83864
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California, 95051
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
About this study
Official title: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.
Read the detailed description
Patients experiencing fatigue related to cancer will be asked to take part in this study. Cancer-related fatigue is a very common symptom in patients with cancer. Patients will receive armodafinil or placebo. Please see the "Arms" section for more details regarding the treatment assignments. The primary objective of this study is to determine preliminary efficacy measured by patient reported fatigue Brief Fatigue Inventory (BFI) at 8 weeks of two doses (150 mg and 250 mg) of armodafinil in treating moderate fatigue compared to placebo in patients with high grade glioma.
The secondary objectives of the study are listed below.
- To evaluate the tolerability at 8 weeks of 150 mg and 250 mg armodafinil in this patient population.
- To assess the effect of armodafinil at 8 weeks on cognitive function in patients with high grade glioma.
- To assess the impact of armodafinil on global quality of life and other fatigue endpoints in this patient population with high grade glioma.
- Explore the correlation between the BFI, Patient-Reported Outcomes Measurement Information System (PROMIS), and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measures, as well as, the relationship of fatigue and cognitive difficulties.
Patients will receive armodafinil or placebo for a total of 8 weeks.
- Conditions
- Fatigue
- Being tested
- armodafinil 150 mg, Placebo, armodafinil 250 mg
- Medical subject headings
- Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
armodafinil 150 mgDrug
given orally
PlaceboOther
given orally
armodafinil 250 mgDrug
given orally
| Study group | Role | What they receive |
|---|---|---|
| Arm I | Experimental | Patients receive 150 mg armodafinil orally every day in the morning for 8 weeks. Receives: Drug: armodafinil 150 mg |
| Arm II | Placebo comparator | Patients receive placebo orally every day in the morning for 8 weeks. Receives: Other: Placebo |
| Arm III | Experimental | Patients receive 250 mg armodafinil orally every day in the morning for 8 weeks. Receives: Drug: armodafinil 250 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Number of Participants With a Response in Terms of a Clinically Meaningful Improvement in Patient-reported Fatigue at 8 Weeks.
A response is defined as an improvement of 2 points on the 0-10 scale of the usual fatigue on the Brief Fatigue Inventory (BFI). The number of participants with a response in terms of a clinically meaningful improvement in patient-reported fatigue at 8 weeks.
Scale: 0 (No fatigue) - 10 (As bad as you can imagine) Interpretation: higher scores mean a worse outcome
Measured: At 8 weeks
Secondary outcomes (4)
Fatigue: Brief Fatigue Inventory (BFI): The Number of Participants With a Response in Terms of a Clinically Meaningful Improvement in Patient-reported Fatigue at 4 Weeks.
A response is defined as an improvement of 2 points on the 0-10 scale of the usual fatigue on the Brief Fatigue Inventory (BFI). The number of participants with a response in terms of a clinically meaningful improvement in patient-reported fatigue at 4 weeks Scale: 0 (No fatigue) - 10 (As bad as you can imagine) Interpretation: higher scores mean a worse outcome
Measured: Up to 4 weeks
Cognitive Function: Assessed by the Change in Z Score for Symbol Digit Modalities Test (SDMT) From Baseline to End of Week 8
The participant is presented with a page headed by a key that pairs the single digits 1-9 with nine symbols. Rows below contain only symbols, the subject's task is to orally report the correct number in the spaces below. After completing the first 10 items with guidance, the subject is timed to determine how many responses can be made in 90 seconds. Range score: not applicable. Higher scores mean a better outcome. Explored domain: Sustained attention and information processing speed. Each neuropsychological measure was converted to an age-normative z score using published normative data. Impaired SDMT performance was defined as falling one standard deviation or more below the normative mean.
Measured: Up to 8 weeks
Change in Quality of Life as Measured by Linear Analogue Self Assessment (LASA) From Baseline to End of Weeks 4 and 8
Quality of life: Linear Analogue Self Assessment (LASA) will be analyzed comparing the total score for each treatment testing for change from baseline to four and eight weeks. Linear Analogue Self Assessment (LASA) is a 12 global QOL tool to which measures 10 subscales: overall QOL, physical well-being, fatigue, frequency and severity of pain, as well as social functioning and spiritual, emotional and mental well-being. All subscales were converted to a scale of 0-100, with higher scores indicating better QOL. Total score is the average of all 10 subscales.
Measured: Up to 8 weeks
Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events Deemed at Least Possibly Related to Treatment Via the CTCAE Version 4.0
The number of participants who experienced at least one grade 3 or higher adverse events deemed at least possibly related to treatment via the CTCAE version 4.0
Measured: Up to 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Feb 2013 (estimated)
- Study start21 Jun 2013
- Primary completionMay 2019
- Study completion15 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for FatigueStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 328 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Alyx B. Porter Umphrey, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01781468
- Sponsor's protocol ID
- A221101
- Other IDs
- N10C3, NCI-2012-02020, U10CA037404, U10CA037447, UG1CA189823
- Status last verified
- Jan 2025
- First submitted
- 29 Jan 2013
- Last updated
- 27 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: IPD that underlie results in the publication PubMed ID 34882169.
Publications
Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD. Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Feb 1;8(2):259-267. doi: 10.1001/jamaoncol.2021.5948.
PubMed 34882169
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
- ClinicalTrials.gov ID
- NCT01781468
- Acronym / sponsor ID
- A221101
- Conditions
- Fatigue
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 328 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 21 Jun 2013 (actual)
- Primary completion
- May 2019 (actual)
- Study completion
- 15 Dec 2019 (actual)
- First posted
- 1 Feb 2013 (estimated)
- Results
- Posted 7 May 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.
Detailed description
Patients experiencing fatigue related to cancer will be asked to take part in this study. Cancer-related fatigue is a very common symptom in patients with cancer. Patients will receive armodafinil or placebo. Please see the "Arms" section for more details regarding the treatment assignments. The primary objective of this study is to determine preliminary efficacy measured by patient reported fatigue Brief Fatigue Inventory (BFI) at 8 weeks of two doses (150 mg and 250 mg) of armodafinil in treating moderate fatigue compared to placebo in patients with high grade glioma.
The secondary objectives of the study are listed below.
- To evaluate the tolerability at 8 weeks of 150 mg and 250 mg armodafinil in this patient population.
- To assess the effect of armodafinil at 8 weeks on cognitive function in patients with high grade glioma.
- To assess the impact of armodafinil on global quality of life and other fatigue endpoints in this patient population with high grade glioma.
- Explore the correlation between the BFI, Patient-Reported Outcomes Measurement Information System (PROMIS), and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measures, as well as, the relationship of fatigue and cognitive difficulties.
Patients will receive armodafinil or placebo for a total of 8 weeks.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm I | Experimental | Drug: armodafinil 150 mgPatients receive 150 mg armodafinil orally every day in the morning for 8 weeks. |
| Arm II | Placebo comparator | Other: PlaceboPatients receive placebo orally every day in the morning for 8 weeks. |
| Arm III | Experimental | Drug: armodafinil 250 mgPatients receive 250 mg armodafinil orally every day in the morning for 8 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma who are clinically stable and have completed radiation therapy (excluding stereotactic radiosurgery) > 21 days and =< 24 months prior to enrollment; NOTE: clinical stability will be defined as a stable or improved Karnofsky performance status (KPS) compared to the prior month
- >= 6 score on the worst fatigue question of the BFI (Brief Fatigue Inventory, question 3); it is not required for the patient to complete the entire BFI to meet this criterion
- Undergone surgery (gross total or subtotal resection) or biopsy and will have been treated with concurrent radiation therapy and chemotherapy as standard of care for glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma patients; Note: radiation must be completed, but chemotherapy is allowed; patients who are currently using Optune device will be eligible to participate in this trial
- Negative serum pregnancy test done =< 7 days prior to registration only for women determined to be of childbearing potential by their treating physician
- Ability to complete questionnaire(s) by themselves or with assistance
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| armodafinil 150 mggiven orally | Drug | Arm I |
| Placebogiven orally | Other | Arm II |
| armodafinil 250 mggiven orally | Drug | Arm III |
Primary outcome
The Number of Participants With a Response in Terms of a Clinically Meaningful Improvement in Patient-reported Fatigue at 8 Weeks.
Time frame: At 8 weeks
A response is defined as an improvement of 2 points on the 0-10 scale of the usual fatigue on the Brief Fatigue Inventory (BFI). The number of participants with a response in terms of a clinically meaningful improvement in patient-reported fatigue at 8 weeks. Scale: 0 (No fatigue) - 10 (As bad as you can imagine) Interpretation: higher scores mean a worse outcome
4 secondary outcomes
Fatigue: Brief Fatigue Inventory (BFI): The Number of Participants With a Response in Terms of a Clinically Meaningful Improvement in Patient-reported Fatigue at 4 Weeks.
Time frame: Up to 4 weeks
Cognitive Function: Assessed by the Change in Z Score for Symbol Digit Modalities Test (SDMT) From Baseline to End of Week 8
Time frame: Up to 8 weeks
Change in Quality of Life as Measured by Linear Analogue Self Assessment (LASA) From Baseline to End of Weeks 4 and 8
Time frame: Up to 8 weeks
Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events Deemed at Least Possibly Related to Treatment Via the CTCAE Version 4.0
Time frame: Up to 8 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 34882169Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD. Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Feb 1;8(2):259-267. doi: 10.1001/jamaoncol.2021.5948.
- Individual participant dataSharing planned: Yes. IPD that underlie results in the publication PubMed ID 34882169.
Related trials for Fatigue
Enrolling by invitation
Dance-Based Exercise for Cancer-Related Fatigue in Breast Cancer Patients
Breast Neoplasms
Not yet recruiting
Mind Body Reprogramming Therapy for Adolescents With Chronic Fatigue
Chronic Fatigue
Not yet recruiting
Comparison of Functional Inspiratory Muscle Training and Combined Exercise Training in Individuals With Type 2 Diabetes
Type 2 Diabetes Mellitus
Recruiting
Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling
Athletic Performance, Hyperbaric Oxygenation
Recruiting
Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer"
Muscle Fatigue, Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alyx B. Porter Umphrey, MD study chair
Mayo Clinic
365 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing armodafinil 150 mg and armodafinil 250 mg in people with Fatigue, run by Alliance for Clinical Trials in Oncology at 365 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 365 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Number of Participants With a Response in Terms of a Clinically Meaningful Improvement in Patient-reported Fatigue at 8 Weeks. (time frame: At 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01781468, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2025.